tiprankstipranks
Advertisement
Advertisement

NBIX Stock Latest News

Soleno Therapeutics presents new VYKAT XR data at ENDO 2026
The FlySoleno Therapeutics presents new VYKAT XR data at ENDO 2026
4m ago
NBIX
Neurocrine presents first retrospective case series of Crenessity
PremiumThe Fly
Neurocrine presents first retrospective case series of Crenessity
9m ago
NBIX
Neurocrine presents two-year Crenessity data
PremiumThe Fly
Neurocrine presents two-year Crenessity data
8h ago
NBIX
Neurocrine reports new post-hoc data from KINECT 4 trial
PremiumThe Fly
Neurocrine reports new post-hoc data from KINECT 4 trial
7d ago
NBIX
Neurocrine presents new data showing Improvements with INGREZZA
PremiumThe Fly
Neurocrine presents new data showing Improvements with INGREZZA
7d ago
NBIX
Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
PremiumRatingsMyles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline
13d ago
NBIX
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
Premium
The Fly
Meta Platforms upgraded, Okta downgraded: Wall Street’s top analyst calls
13d ago
KNX
SHW
Neurocrine reinstated with a Buy at Goldman Sachs
Premium
The Fly
Neurocrine reinstated with a Buy at Goldman Sachs
13d ago
NBIX
Neurocrine price target raised to $183 from $180 at RBC Capital
PremiumThe Fly
Neurocrine price target raised to $183 from $180 at RBC Capital
17d ago
NBIX
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
PremiumCompany Announcements
Neurocrine Shareholders Reelect Directors and Approve Governance Measures
18d ago
8K
NBIX
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
PremiumThe Fly
Neurocrine initiated with Outperform at Bernstein on long runway of key drugs
25d ago
NBIX
Neurocrine initiated with an Outperform at Bernstein
PremiumThe Fly
Neurocrine initiated with an Outperform at Bernstein
25d ago
NBIX
Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
PremiumCompany AnnouncementsNeurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors
27d ago
NBIX
Neurocrine announces new data from a clinician survey in Ingrezza
Premium
The Fly
Neurocrine announces new data from a clinician survey in Ingrezza
28d ago
NBIX
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
Premium
Company Announcements
Neurocrine Closes Soleno Deal, Expands Rare Disease Portfolio
28d ago
8K
NBIX
Neurocrine completes acquisition of Soleno Therapeutics
PremiumThe Fly
Neurocrine completes acquisition of Soleno Therapeutics
28d ago
NBIX
SLNO
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
PremiumThe Fly
Aardvark Therapeutics downgraded to Underperform from Buy at BofA
1M ago
AARD
NBIX
Neurocrine price target raised to $185 from $177 at JPMorgan
PremiumThe Fly
Neurocrine price target raised to $185 from $177 at JPMorgan
1M ago
NBIX
Neurocrine price target raised to $155 from $140 at Truist
PremiumThe Fly
Neurocrine price target raised to $155 from $140 at Truist
1M ago
NBIX
Neurocrine price target raised to $155 from $150 at Deutsche Bank
PremiumThe FlyNeurocrine price target raised to $155 from $150 at Deutsche Bank
1M ago
NBIX
Neurocrine treatment of Friedreich ataxia granted orphan designation
Premium
The Fly
Neurocrine treatment of Friedreich ataxia granted orphan designation
1M ago
NBIX
Neurocrine price target raised to $246 from $242 at Citi
Premium
The Fly
Neurocrine price target raised to $246 from $242 at Citi
1M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >